stockrowINmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
- Revenue
- +8.70%
- EPS
- +95.2%
- Free cash flow
- +55.4%
Quarter to June 2026, against a year earlier
Follow INMB
Alert me
INmune Bio, Inc. (INMB) Altman Z-score
INmune Bio, Inc.'s Altman Z-score for fiscal 2025 is −10.46, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −10.46 | (9.08) |
| FY2024 | −1.37 | (3.31) |
| FY2023 | 1.94 | 0.61 |
| FY2022 | 1.33 | (2.76) |
| FY2021 | 4.09 | (59.54) |
| FY2020 | 63.63 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.66 | — | 0.80 | |
| Retained earnings / total assets | (6.46) | — | −9.05 | |
| EBIT / total assets | (1.46) | — | −4.83 | |
| Market value of equity / total liabilities | 4.38 | — | 2.63 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −10.46 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −23.76 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EYPT EyePoint, Inc. compare | 8.5× |
| PTHS Pelthos Therapeutics Inc. compare | −0.8× |
| VERU Veru Inc. compare | −5.8× |
| GRDX GridAI Technologies Corp. compare | −6.6× |
| INMB INmune Bio, Inc. | −10.5× |
| PMN Promis Neurosciences compare | −78.6× |
| IRLA IRulya Therapeutics Inc. compare | — |
| NNVC NanoViricides, Inc. compare | — |
| LIANY LianBio Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets